Gainers

• Kairos Pharma (AMEX:KAPA) stock rose 11.3% to $0.61 during Thursday's after-market session. The market value of their outstanding shares is at $13.0 million.
• Neurogene (NASDAQ:NGNE) shares increased by 6.7% to $21.0. The market value of their outstanding shares is at $311.1 million.
• PharmaCyte Biotech (NASDAQ:PMCB) shares moved upwards by 6.53% to $0.75. The company's market cap stands at $7.3 million.
• Curanex Pharmaceuticals (NASDAQ:CURX) stock moved upwards by 6.32% to $0.49. The market value of their outstanding shares is at $8.9 million.
• Cue Biopharma (NASDAQ:CUE) shares rose 4.16% to $0.3. The company's market cap stands at $25.8 million.
• bioAffinity Technologies (NASDAQ:BIAF) stock rose 3.84% to $1.08. The market value of their outstanding shares is at $4.9 million.

Losers

• BioLine Rx (NASDAQ:BLRX) shares decreased by 11.0% to $2.56 during Thursday's after-market session. The market value of their outstanding shares is at $10.2 million.
• Cypherpunk Technologies (NASDAQ:CYPH) shares declined by 9.15% to $0.63. The market value of their outstanding shares is at $38.8 million.
• VSee Health (NASDAQ:VSEE) shares decreased by 7.14% to $0.35. The market value of their outstanding shares is at $13.9 million.
• Vivos Therapeutics (NASDAQ:VVOS) shares fell 6.21% to $1.36. The market value of their outstanding shares is at $16.7 million.
• Dentsply Sirona (NASDAQ:XRAY) shares declined by 5.98% to $11.95. The company's market cap stands at $2.5 billion. As per the press release, Q4 earnings came out today.
• Progyny (NASDAQ:PGNY) shares declined by 5.62% to $21.0. The market value of their outstanding shares is at $1.8 billion. The company's, Q4 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.